Manufacturer of Controlled Substances; Notice of Application, 22704 [05-8693]

Download as PDF 22704 Federal Register / Vol. 70, No. 83 / Monday, May 2, 2005 / Notices (6) An estimate of the total public burden (in hours) associated with the collection: The estimated total public burden associated with the Web submission form will be 19,200 hours annually, while bulk data extraction is estimated at 576 hours annually. If additional information is required contact: Brenda E. Dyer, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street NW., Washington, DC 20530. Dated: April 25, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–8694 Filed 4–29–05; 8:45 am] Dated: April 25, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–8693 Filed 4–29–05; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P Dated: April 27, 2005. Brenda E. Dyer, Department Clearance Officer, United States Department of Justice. [FR Doc. 05–8680 Filed 4–29–05; 8:45 am] Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 5, 2005, Roche Diagnostics Operations Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application 19:05 Apr 29, 2005 Jkt 205001 Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Drug Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 18, 2005, Lilly Del Caribe, Inc., Chemical Plant, Kilometer 146.7, State Road 2, Mayaguez, Puerto Rico 00680, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Dextropropoxyphene (9273), a basic class of controlled substance listed in Schedules II. The company plans to manufacture the listed controlled substance in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than July 1, 2005. VerDate jul<14>2003 DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Schedule Lysergic Acid Diethylamide (7315) Tetrahydrocannabinol (7370) ....... Alphamethadol (9605) .................. Phencyclidine (7471) .................... Benzoylecgonine (9180) ............... Methadone (9250) ........................ Morphine (9300) ........................... I I I II II II II The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than July 1, 2005. PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 Federal Bureau of Investigation Agency Information Collection Activities: Proposed Collection; Comments Requested 30-Day Notice of Information Collection Under Review: Voluntary Appeal File (VAF) Brochure. ACTION: The Department of Justice (DOJ), Federal Bureau of Investigation (FBI) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the Federal Register Volume 69, Number 218, page 65455 on November 12, 2004, allowing for a 60 day comment period. The purpose of this notice is to allow for an additional 30 days for public comment until June 1, 2005. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to (202) 395–5806. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; E:\FR\FM\02MYN1.SGM 02MYN1

Agencies

[Federal Register Volume 70, Number 83 (Monday, May 2, 2005)]
[Notices]
[Page 22704]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8693]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 5, 2005, Roche 
Diagnostics Operations Inc., Attn: Regulatory Compliance, 9115 Hague 
Road, Indianapolis, Indiana 46250, made application by renewal to the 
Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic Acid Diethylamide (7315)..........  I
Tetrahydrocannabinol (7370)................  I
Alphamethadol (9605).......................  I
Phencyclidine (7471).......................  II
Benzoylecgonine (9180).....................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than July 1, 2005.

    Dated: April 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-8693 Filed 4-29-05; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.